Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cardiff Oncology Inc

CRDF
Current price
1.26 USD +0.04 USD (+3.28%)
Last closed 1.23 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 54 506 184 USD
Yield for 12 month -19.23 %
Week
Month
Year
CRDF
21.11.2021 - 28.11.2021

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. It primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Address: 11055 Flintkote Avenue, San Diego, CA, United States, 92121

Analytics

WallStreet Target Price

8.5 USD

P/E ratio

Dividend Yield

Current Year

+386 000 USD

Last Year

+359 000 USD

Current Quarter

+141 000 USD

Last Quarter

+108 000 USD

Current Year

+386 000 USD

Last Year

+359 000 USD

Current Quarter

+141 000 USD

Last Quarter

+108 000 USD

Key Figures CRDF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -44 091 000 USD
Operating Margin TTM -7673.76 %
PE Ratio
Return On Assets TTM -26.21 %
PEG Ratio
Return On Equity TTM -42.72 %
Wall Street Target Price 8.5 USD
Revenue TTM 460 000 USD
Book Value 1.74 USD
Revenue Per Share TTM 0.01 USD
Dividend Share
Quarterly Revenue Growth YOY 51.6 %
Dividend Yield
Gross Profit TTM -26 721 000 USD
Earnings Share -0.92 USD
Diluted Eps TTM -0.92 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CRDF

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CRDF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:6
Payout Ratio
Last Split Date 20.02.2019
Dividend Date 20.02.2019

Stock Valuation CRDF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 482.7446
Price Sales TTM 159.9695
Enterprise Value EBITDA -9.3784
Price Book MRQ 0.5643

Financials CRDF

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CRDF

For 52 weeks

0.94 USD 2.79 USD
50 Day MA 1.23 USD
Shares Short Prior Month 1 528 003
200 Day MA 1.56 USD
Short Ratio 4.65
Shares Short 1 626 822
Short Percent 3.75 %